Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “microbial interactions”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,189 records · Page 66Linked to original sources
PubMed2004

In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates.

OBJECTIVES: There is very little information, to date, on the antifungal activity of bergamot oil. In this study, we investigated the in vitro activity of three bergamot oils (natural essence, furocoumarin-free extract and distilled extract) against clinically relevant Candida species. We studied the two derivatives, components of Italian pharmaceutical products, that are supposed to be less toxic than the essential oil. METHODS: In vitro susceptibility of 40 clinical isolates of Candida spp. (Candida albicans, n=20; Candida glabrata, n=13; Candida krusei, n=4; Candida tropicalis, n=2; Candida parapsilosis, n=1), associated with symptomatic and asymptomatic vulvovaginal candidiasis, was determined using a modification of the NCCLS M27-A2 broth microdilution method. MICs were evaluated for each of the oils alone and combined with sub-inhibitory concentrations of the well-known antiseptic, boric acid. To boric acid, all isolates had MIC values ranging from 0.094% to 0.187% (w/v). RESULTS: At 24 h readings, the MIC(90 )s (for all isolates) were (v/v): 5% for natural essence of bergamot, 2.5% for the furocoumarin-free extract, and 1.25% for the distilled extract. At the 48 h reading, these values increased to >10%, 5% and 2.5%, respectively. At both readings, MIC(90 )s for all oil+boric acid combinations were significantly lower than corresponding values for the oils alone (P <0.05). CONCLUSIONS: These data indicate that bergamot oils are active in vitro against Candida spp., suggesting their potential role for the topical treatment of Candida infections.

Antifungal Agents↗
PubMed1995

Bactericidal activity of skin disinfectants on methicillin-resistant Staphylococcus aureus.

We studied bactericidal activity of 10% povidone-iodine, 0.5% chlorhexidine gluconate, and 0.5% chlorhexidine in 80% ethanol on four strains of methicillin-resistant and two strains of methicillin-susceptible Staphylococcus aureus. The pathogen was exposed to each of the disinfectants for 15, 30, 60, 120, and 240 s at room temperature. The inocula from these suspensions were cultured 72 h at 37 degrees C after the antimicrobial activity of the disinfectants in the suspensions was inactivated by 1:1000 dilution with neutralizer. No organism grew in any of the strains after exposure to 0.5% chlorhexidine in 80% ethanol. The 15-, 30-, and 60-s exposure to 10% povidone-iodine reduced the mean colony count by 55.2%, 91.2%, and 96.7%, respectively, and the exposures to 0.5% chlorhexidine gluconate reduced the mean colony count by 37.2%, 77.1%, and 93.3%, respectively. The difference in colony count between disinfectants was significant at 15- and 30-s exposures (P < 0.01 and 0.05, respectively). The results suggest that bactericidal activity of 0.5% chlorhexidine in 80% ethanol is more potent and more rapid against methicillin-susceptible and methicillin-resistant strains of S. aureus.

Chlorhexidine↗
PubMed1996

Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team.

We performed a pilot study that examined the clinical and pharmacokinetic interactions between zidovudine (ZDV) and a pyridinone derivative, L-697-661. The results indicate that the drugs were well tolerated, with no important pharmacokinetic interactions, when administered concomitantly for as long as 8 weeks. Although the number of study participants was small, we noted rapid emergence of resistance to L-697,661 among ZDV-naive study subjects who were administered L-697,661 as monotherapy but did not observe isolates of human immunodeficiency virus type 1 (HIV-1) resistant to L-697,661 among those who were administered concomitant ZDV. These results suggest a potential interaction between development of resistance to L-697,661 and ZDV. Although the clinical development of L-697,661 has been halted, our results support the need for further studies to test whether specific interactions among antiretroviral agents administered in combination and the molecular target can delay the emergence of isolates that exhibit resistance to all drugs in the regimen.

Adult↗
PubMed1997

Prevention of opportunistic infections in the era of improved antiretroviral therapy.

Patients with advanced human immunodeficiency virus (HIV) infection who are severely immunosuppressed develop a variety of opportunistic infections that have a significant impact on their well-being, quality of life, health-care costs, and survival. The risk for development of opportunistic infections depends on exposure to potential pathogens, the virulence of the pathogens, the degree of host immunity, and the use of antimicrobial prophylaxis. Many studies have confirmed the benefits of prophylaxis in severely immunosuppressed patients. Factors that affect the use of prophylaxis for prevention of opportunistic infections in HIV-infected patients include the prevalence and potential severity of the disease, ease of treatment if infection occurs, the cost-effectiveness of the prophylactic regimen, and the potential for increased survival, drug toxicity, drug interactions, and emergence of resistance with the regimen. The United States Public Health Service and the Infectious Diseases Society of America (USPHS/IDSA) have established disease-specific recommendations for use of prophylaxis for opportunistic infections in HIV-infected patients. These guidelines identify regimens that are strongly recommended as standards of care, regimens that should be seriously considered in selected patients, and regimens that are not routinely indicated but may be considered in selected patients. Although further study is needed, advances in antiretroviral therapy may have an important impact on the recommendations for prophylaxis and may eventually allow discontinuation of these regimens in patients who regain functional immunity.

AIDS-Related Opportunistic Infections↗
PubMedDate not supplied

Effect of chloroquine on the bioavailability of ciprofloxacin in humans.

Chloroquine, a front-line drug in the treatment of malaria, has developed widespread resistance, especially to the Plasmodium falciparum strains. Ciprofloxacin is a second-generation quinolone used as a broad-spectrum fluoroquinolone antibacterial agent. The possibility of using ciprofloxacin as an antimalarial, especially in chloroquine-resistant strains, is very promising. They concluded from in vitro studies however that the anti-malarial effect occur at high dose level of ciprofloxacin to achieve the required serum concentrations. Studies have shown that there is little interstrain variability in the in vitro susceptibility of P. falciparum to fluoroquinolones. There is also no cross-resistance between them. Another study stated that 50% inhibition of parasite growth in vitro required 6.6 microg/mL after a high dose of ciprofloxacin was used. They thus concluded that ciprofloxacin should not be used alone. There is need for in vivo studies to ascertain the achievable serum concentration of ciprofloxacin when given alone and when given in combination with chloroquine. The serum concentration of ciprofloxacin was studied when ciprofloxacin was given alone and in combination with chloroquine in humans. Five healthy male volunteers aged (19-31) years who were not taking any of the prescribed medications and had no sensitivity to either ciprofloxacin or chloroquine, each received 500 mg ciprofloxacin orally with 250 mL of water, and after a 2-week wash-out period, 500 mg ciprofloxacin plus 600 mg of chloroquine was administered orally with 250 mL of water after informed consent. A blood sample (2.5 mL) was collected just before taking the drug at 8:00 AM representing 0 hours and continued afterward at 1, 2, 4, 8, 12, and 24 hours the following day. Serum samples were stored at -20 degrees C until analyzed. The minimal inhibitory concentrations (MIC) by diffusion through agar technique was used for the assay of serum ciprofloxacin. The following bioavailability parameters: Cmax, tmax, and AUC 0-24, AUC 0-infinity were calculated. The peak serum concentration Cmax of ciprofloxacin was 3.42 +/- 0.32 microg/mL, which dropped to 2.8 +/- 0.18 microg/mL when chloroquine was taken together with ciprofloxacin. These values were less than the in vitro 12.5 microg/mL concentrations required to inhibit P. falciparum. Though the effect of parasitemia was not ascertained, the in vivo use of ciprofloxacin alone or in combination is doubtful because increasing the dose that will reach the in vitro level will lead to toxicity in vivo.

Adult↗
PubMed1989

Interactions of the 4-quinolones with other antibacterials.

The effect of sub-inhibitory concentrations of 16 antibacterials on the bactericidal activity of the 4-quinolones nalidixic acid, ciprofloxacin and ofloxacin against Escherichia coli KL16 in nutrient broth was investigated. Sub-inhibitory concentrations of rifampicin, clindamycin, chloramphenicol, erythromycin or tetracycline antagonised the bactericidal activity of the 4-quinolones. Conversely, all seven aminoglycosides tested enhanced the bactericidal activity of the 4-quinolones whereas the cell wall antagonists, azlocillin, mezlocillin, ceftazidime and vancomycin had no effect on the bactericidal activity of the 4-quinolones.

Anti-Bacterial Agents↗
PubMed2006

Type IV pili and type II secretion play a limited role in Legionella pneumophila biofilm colonization and retention.

Legionellae colonize biofilms in building water systems, yet little is known about their interaction with the organisms in these microbial communities. The role of Legionella pneumophila type IV pili and the type II secretion pre-pilin peptidase was evaluated in a model biofilm system. L. pneumophila strains 130b (wild-type), BS100 (a type IV pili mutant) and NU243 (a pre-pilin peptidase mutant) were assessed for attachment and retention in an established biofilm. Strains 130b and NU243 colonized the biofilm at a similar level while BS100 attached at a tenfold lower level. Over time, NU243 dropped below the level of detection while BS100 remained in the biofilm throughout the course of the experiment. The wild-type strain decreased but remained at a considerably higher level than either of the mutants. Inclusion of amoebae with BS100 allowed for attachment and retention at a level similar to 130b. NU243, which displays reduced intracellular replication, was able to establish itself and persist in the presence of amoebae. Thus, type IV pili and the pre-pilin peptidase facilitate L. pneumophila colonization of biofilms but are not required in the presence of a host for intracellular replication.

Amoebida↗
PubMed1992

Effect of polysaccharide interactions on antibiotic susceptibility of Pseudomonas aeruginosa.

The relative viscosity of Pseudomonas aeruginosa alginate was shown to increase markedly when combined with mucin, Ca2+ ions and the exopolysaccharide from Pseudomonas cepacia. The presence of such a heterodisperse polysaccharide solution significantly reduced the diffusion and hence antimicrobial activity of tobramycin and to a lesser extent ciprofloxacin against Ps. aeruginosa by factors of 90 and 2.5-fold respectively over a 5 h incubation period. The clinical implications of these results are discussed in relation to cystic fibrosis.

Burkholderia cepacia↗
PubMed2006

Guaijaverin -- a plant flavonoid as potential antiplaque agent against Streptococcus mutans.

AIMS: The aim of the present study was to investigate the anti-Streptococcus mutans activity and the in vitro effects of subminimal inhibitory concentrations of guaijaverin isolated from Psidium guajava Linn. on cariogenic properties of Strep. mutans. METHODS AND RESULTS: Bioautography-directed chromatographic fractionation, yield biologically active compound, quercetin-3-O-alpha-l-arabinopyranoside (guaijaverin), from crude methanol extract of P. guajava. Growth-inhibitory activity of the compound against Strep. mutans of both clinical and type strain cultures was evaluated. The anti-Strep. mutans activity of the guaijaverin was found to be bacteriostatic, both heat and acid stable and alkali labile with the minimum inhibitory concentration (MIC) of 4 mg ml(-1) for MTCC 1943 and 2 mg ml(-1) for CLSM 001. The sub-MIC concentrations (0.0078-2 mg ml(-1)) of the guaijaverin were evaluated for its cariogenic properties such as acid production, cell-surface hydrophobicity, sucrose-dependent adherence to glass surface and sucrose-induced aggregation of Strep. mutans. CONCLUSIONS: The active flavonoid compound, quercetin-3-O-alpha-l-arabinopyranoside (guaijaverin) demonstrated high potential antiplaque agent by inhibiting the growth of the Strep. mutans. SIGNIFICANCE AND IMPACT OF THE STUDY: This study demonstrated the new growth-inhibitory compound guaijaverin against Strep. mutans and led to the acceptance of traditional medicine and natural products as an alternative form of health care.

Bacterial Adhesion↗
PubMed1996

Fluoroquinolones in animal health.

The fluoroquinolones are a series of synthetic antibacterial agents that are undergoing extensive investigation for both human and veterinary use in the treatment of a variety of bacterial infections. These agents work through the inhibition of DNA gyrase, interfering with the supercoiling of bacterial chromosomal material. As a result, these agents are rapidly bactericidal primarily against gram-negative bacteria, mycoplasma, and some gram-positive bacteria, with most having little to no activity against group D streptococci and obligate anaerobic bacteria. Resistance develops slowly and is almost always chromosomal and not plasmid-mediated. However, development of resistance to the fluoroquinolones and transfer of that resistance among animal and human pathogens have become a hotly debated issue among microbiologists. The fluoroquinolones are a current antimicrobial class whose use in veterinary medicine is being scrutinized. From a pharmacokinetic perspective, these agents are variably but well absorbed from the gastrointestinal tract and almost completely absorbed from parenteral injection sites, and they are well distributed to various tissues in the body. The fluoroquinolones are metabolized and renally excreted, with many of them having approximately equal excretion by the hepatic and the renal excretory systems. The primary toxicity observed at therapeutic doses involves the gastrointestinal system and phototoxicity, although at higher doses central nervous system toxicity and ocular cataracts are observed. Administration to immature animals may result in erosive arthropathies at weight-bearing joints, and administration of high doses to pregnant animals results in maternotoxicity and occasionally embryonic death. The fluoroquinolones are approved for indications such as urinary tract infections and soft tissue infections in dogs and cats and colibacillosis in poultry. Approval for bovine respiratory disease in the United States is being sought. Other indications for which the fluoroquinolones have been used in animal health include deep-seated infections, prostatitis, and other bacterial infections resistant to standard antimicrobial therapy.

Administration, Oral↗
PubMed1994

In vitro interactions of neomycin sulfate, bacitracin, and polymyxin B sulfate.

BACKGROUND: Neomycin sulfate, bacitracin, and polymyxin B sulfate have been combined in topical preparations to provide a complementary antimicrobial spectrum for the prevention of minor wound infections. The advisability of the inclusion of neomycin sulfate has been questioned since it may cause contact sensitization. METHODS: To assess the value of neomycin, microdilution checkerboard titrations were used to determine the in vitro interactions between two-antibiotic and three-antibiotic combinations against reference strains of bacteria commonly associated with wound infections. Using Fractional Inhibitory Concentration (FIC) indices (< 0.5 indicates synergism with two-drug combinations), the combination of neomycin/bacitracin was synergistic for both S. aureus and Ps. aeruginosa; neomycin/polymyxin B was synergistic for E. faecalis, and the bacitracin/polymyxin B combination was synergistic against Ps. aeruginosa. A three-drug combination of neomycin/bacitracin/polymyxin B had FIC values of < 1 for all organisms, indicating synergy and substantiating the clinical role of neomycin sulfate in current topical formulations. RESULTS: Neomycin has the lowest safety profile of the drugs in this combination. A replacement agent should ideally have similar or superior synergistic capabilities with the remaining drugs and contribute to the therapeutic efficacy of the preparation. Additionally, because of the strongly synergistic tendencies displayed by the three-drug combination, it may be possible to reduce the antibiotic concentrations present in current formulations. CONCLUSION: By developing this concept, there is potential for the formulation of topical preparations to be based on a sound theoretical and clinical rationale.

Bacitracin↗